To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone

The recently published phase II prospective SWITCH trial evaluated whether patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate could benefit from a ‘steroid switch’ from prednisone to dexamethasone. A total of 26 patients, both chemonaïve (14 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanardi, Elisa, Soldato, Davide, Latocca, Maria Maddalena, Cattrini, Carlo, Boccardo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560791/
https://www.ncbi.nlm.nih.gov/pubmed/31217821
http://dx.doi.org/10.1177/1756287219854908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560791/
https://www.ncbi.nlm.nih.gov/pubmed/31217821
http://dx.doi.org/10.1177/1756287219854908

Ejemplares similares